Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

There was no difference between the groups with regard to changes in the Zung Depression Scale, Beck Anxiety ... option for the control of neuropathic pain in patients with cancer, and appears ...

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal ...

Brief pain inventory; LANSS: Leeds assessment of neuropathic symptoms and signs; MPQ: McGill pain questionnaire; NPS: Neuropathic pain scale; NRS: Numerical rating scale; VAS: Visual analog score.

Neuropathic corneal pain, often resulting from conditions like ... staining” as measured by the Ora Calibra Staining Scale as early as Day 29 (p = 0.034). OK-101 also improved at least two ...

H.C. Wainwright reiterated its Buy rating on OKYO Pharma Ltd. (NASDAQ: OKYO) with a price target of $7.00, representing significant upside potential from the current trading price of $1.10. According ...

Accurate pain reporting in sickle cell disease is critical to effective pain assessment and management, but accuracy depends on patient comprehension of forms.

Mirogabalin, a nerve pain drug, may help manage post-traumatic trigeminal neuropathic (PTTN) occlusal pain following ... Patients recorded daily changes in pain intensity using a visual analog scale ...

Clinical Updates: OK-101 Neuropathic Corneal OKYO Pharma ... 101 demonstrated statistically significant pain relief as measured by visual analogue scale (VAS) from Day 29 through the last study ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...